drugset / Trial / NCT01318135
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).
Timeline
- Start
- 2009-01
- Primary completion
- 2010-01
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alogliptin | Unknown | 12.5 mg | Oral |
| Comparator | Alogliptin | Unknown | 25 mg | Oral |
| Comparator | Glimepiride | Small molecule | 1 mg | Oral |
| Comparator | Glimepiride | Small molecule | 2 mg | Oral |
| Comparator | Glimepiride | Small molecule | 3 mg | Oral |
| Comparator | Glimepiride | Small molecule | 4 mg | Oral |
| Comparator | Glimepiride | Small molecule | 5 mg | Oral |
| Comparator | Glimepiride | Small molecule | 6 mg | Oral |
| Comparator | Metformin | Small molecule | 500 mg | Oral |
| Comparator | Metformin | Small molecule | 750 mg | Oral |